Colistimethate Sodium products: information for supporting intrathecal risk assessment

11 August 2022Colistimethate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Compatibility of nebuliser solution combinations

22 June 2022Guidance on what to consider when mixing nebuliser solutions and advice on which combinations are compatible.

Safety in Lactation: Some other antibacterials

4 November 2020Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to…
Search Articles

Lactation Safety Information

Minimal absorption from the infant's GI tract
No published evidence of safety
Small amounts in breast milk
24 September 2020

New Medicines


Licence extension / variation

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials


The pentasodium salt derivative of colistin, a polypeptide antibiotic produced by Bacillus polymyxa var. colistinus
A large study across 640 general practices in the UK found that prevalence in 2011 in men was 227 per 100,000, and 309 per 100,000 in women. It is estimated that around 1,000 people die each year from bronchiectasis in England and Wales. Chronic colonisation by P. aeruginosa, severe exacerbations, and systemic inflammation (raised C-reactive protein) are associated with disease progression in non-cystic fibrosis bronchiectasis. 10% of adults die within 5-8 years of diagnosis [1].
Non-cystic fibrosis (CF)-related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa